Alastair D. Burt

Biliary epithelial-mesenchymal transition in posttransplantation recurrence of primary biliary cirrhosis.

Liver fibrosis.

Fibrosis and cirrhosis reversibility - molecular mechanisms.

Non-alcoholic fatty liver disease in older people.

The c-Rel subunit of nuclear factor-kappaB regulates murine liver inflammation, wound-healing, and hepatocyte proliferation.

T cell-mediated biliary epithelial-to-mesenchymal transition in liver allograft rejection.

Abrikosoff's Tumor and the Hepatobiliary System: A Curiosa Revisited.

Disrupted pancreatic exocrine differentiation and malabsorption in response to chronic elevated systemic glucocorticoid.

Glucokinase links Krüppel-like factor 6 to the regulation of hepatic insulin sensitivity in nonalcoholic fatty liver disease.

Stimulating healthy tissue regeneration by targeting the 5-HT₂B receptor in chronic liver disease.

Histone methyltransferase ASH1 orchestrates fibrogenic gene transcription during myofibroblast transdifferentiation.

Chemotherapy-associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis.

Multigenerational epigenetic adaptation of the hepatic wound-healing response.

Inhibition of RelA-Ser536 phosphorylation by a competing peptide reduces mouse liver fibrosis without blocking the innate immune response.

Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels?

White cell count and platelet count associate with histological alcoholic hepatitis in jaundiced harmful drinkers.

Development of a robust protocol for gene expression analysis using formalin-fixed, paraffin-embedded liver transplant biopsy specimens.

Clinical but not histological factors predict long-term prognosis in patients with histologically advanced non-decompensated alcoholic liver disease.

Identification of a neuronal transcription factor network involved in medulloblastoma development.

Serum immunoglobulin levels predict fibrosis in patients with non-alcoholic fatty liver disease.

Well-differentiated hepatocellular neoplasm of uncertain malignant potential: proposal for a new diagnostic category.

TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease.

Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.

DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.

Well-differentiated hepatocellular neoplasm of uncertain malignant potential--reply.

Diagnosis and Assessment of NAFLD: Definitions and Histopathological Classification.

Abstracts from the 3rd International Genomic Medicine Conference (3rd IGMC 2015) : Jeddah, Kingdom of Saudi Arabia. 30 November - 3 December 2015.

Exercise Reduces Liver Lipids and Visceral Adiposity in Patients With Nonalcoholic Steatohepatitis in a Randomized Controlled Trial.

Sulfatase-2: a prognostic biomarker and candidate therapeutic target in patients with pancreatic ductal adenocarcinoma.

A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis.

Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity.

Data set for the reporting of intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma and hepatocellular carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR).

Author Correction: Inflammation-induced IgA cells dismantle anti-liver cancer immunity.

The degree of hepatic steatosis associates with impaired cardiac and autonomic function.

Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort.

Fifty years of impact on liver pathology: a history of the Gnomes.

The Balance of Stromal BMP Signaling Mediated by GREM1 and ISLR Drives Colorectal Carcinogenesis.

Corrigendum to: "Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort"☆ (J Hepatol [2020] 505-515).

A Role in the Genetic Predisposition to NAFLD-HCC?